Showing 1271-1280 of 20877 results for "".
- Nirsevimab Real‑world Effectiveness and Early Pathogen Shifts in Italian Infant LRTI Hospitalizationshttps://reachmd.com/news/nirsevimab-realworld-effectiveness-and-early-pathogen-shifts-in-italian-infant-lrti-hospitalizations/2485883/A nationwide, retrospective multicenter analysis across 19 Italian pediatric centers describes infants hospitalized for lower respiratory tract infection (LRTI) during the first RSV season after nirs
- Dapiglutide Phase IIa: Safety, Modest Metabolic Signals but No Significant Weight Benefit at 12 Weekshttps://reachmd.com/news/dapiglutide-phase-iia-safety-modest-metabolic-signals-but-no-significant-weight-benefit-at-12-weeks/2485891/A randomized, double-blind phase IIa trial in adults with obesity evaluated weekly dapiglutide, described as a dual GLP-1/GLP-2 receptor agonist, versu
- Boosters Restore SARS‑CoV‑2 Immunity in Kidney Transplant Recipientshttps://reachmd.com/news/boosters-restore-sarscov2-immunity-in-kidney-transplant-recipients/2485853/In the RECOVAC study, investigators compared kidney transplant recipients (KTRs) who seroconverted after primary vaccination with those who se
- Polyphenol Interventions and Bifidobacterium: Key Findings from a Recent Systematic Reviewhttps://reachmd.com/news/polyphenol-interventions-and-bifidobacterium-key-findings-from-a-recent-systematic-review/2485861/A full systematic review and meta-analysis synthesizes human dietary polyphenol intervention studies that assessed changes in gut microbiota, highlightin
- Phase III SIMBA: MB09 vs Prolia — Key Efficacy, PK/PD, Safety Findingshttps://reachmd.com/news/phase-iii-simba-mb09-vs-prolia-key-efficacy-pkpd-safety-findings/2485867/The published SIMBA phase III article reports a randomized, double-blind comparison of MB09 (a denosumab biosimilar) versus reference denosumab (Prolia)
- Quantitative PET/MRI Framework to Identify LATEhttps://reachmd.com/news/quantitative-petmri-framework-to-identify-late/2485854/An abstract on LATE describes a quantitative 18F-FDG PET– and MRI-volumetry–based framework intended to help identify LATE
- Pre‑Exposure Intranasal Neomycin and Influenza B Transmission: Animal Model Findingshttps://reachmd.com/news/preexposure-intranasal-neomycin-and-influenza-b-transmission-animal-model-findings/2485863/Controlled influenza B transmission experiments in two animal models tested pre-exposure intranasal neomycin sulfate, with outcomes described as differin
- WHO Recommendations for 2026–2027 Northern Hemisphere Influenza Vaccine Compositionhttps://reachmd.com/news/who-recommendations-for-20262027-northern-hemisphere-influenza-vaccine-composition/2485870/The World Health Organization (WHO) reported its recommended viral composition
- Study: Bimekizumab Not Linked to Higher Depression Risk vs. IL-23 Inhibitorshttps://reachmd.com/news/study-bimekizumab-not-linked-to-higher-depression-risk-vs-il-23-inhibitors/2485849/Bimekizumab was not associated with increased risk of depression or suicidal ideation compared with IL-23 inhibitors, a new study from George Washington University indicated. "Bimekizumab, a dual IL-17A/F inhibitor, has demons
- Analysis: Tapinarof Cream Yields Improved Sleep in Pediatric ADhttps://reachmd.com/news/analysis-links-tapinarof-cream-to-early-sleep-improvements-in-pediatric-ad/2485802/A new analysis of the phase 3 ADORING 1 and ADORING 2 trials showed that tapinarof cream, 1% (VTAMA, Organon) was associated with early and sustained improvements in sleep-related patient-reported outcomes in pediatric patients with moderate to severe atopic derma